ADAR1 Capital Management, LLC Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001940272

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidHealth TiltHigh Turnover how tags are computed

Q3 2026 · 259 positions · Total reported value $1.98B · Top-10 concentration 37.7% · Updated 2026-11-16

Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR

Turnover: 45.8% · 33 new · 63 cut · 42 exited

Active Share (vs S&P 500): 99.0% · vs QQQ: 99.5% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q2 2026 → Q3 2026): -7.0% · vs SPY -9.1% · Prev Value $1.81B — last quarter positions weighted by this quarter price moves · ranking

Est. QTD Return (Q3 2026 → newest close): -4.2% · vs SPY -6.4% · Latest Value $1.98B — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking

In its Q3 2026 13F filing, ADAR1 Capital Management, LLC disclosed 259 equity positions with a combined reported value of $1.98B. The filing implies a moderately concentrated portfolio: its ten largest positions account for 37.7% of reported value. HoldingsHub classifies the profile as Mid / Health Tilt / High Turnover.

The largest disclosed positions as of Q3 2026 were SPY ($135.46M), PTGX ($134.04M), ROIV ($112.62M). By sector, the heaviest allocations are Health Care 85.7%, Financials 3.1%. Versus the prior quarter, allocation shifted toward Other (+0.5pp) and away from Health Care (-0.8pp).

Versus the prior quarter, ADAR1 Capital Management, LLC opened 33 new positions, trimmed 63 and fully exited 42, a turnover rate of 45.8% of positions. The portfolio's overlap with the prior quarter was 75% of names.

The largest new positions opened in Q3 2026 were ABCL ($12.00M), BEAM ($10.29M), ENTX ($7.64M).

Of the 42 positions fully exited versus the prior quarter, the largest were CRNX ($45.73M), IWM ($18.78M), XBI ($10.67M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q3 2026)

  • ABCL ABCELLERA BIOLOGICS INC · $12.00M
  • BEAM BEAM THERAPEUTICS INC · $10.29M
  • ENTX ENTERA BIO LTD · $7.64M
  • KRSP RAINIER ACQUISITION CORP · $7.55M
  • DXYZ DESTINY TECH100 INC · $6.49M
  • DARE YARROW BIOSCIENCE INC · $6.37M
  • TLGYF TCGX ACQUISITION CORP · $6.26M
  • RACD RESEARCH ALLIANCE CORP IV · $6.22M

Fully Exited (vs previous quarter)

  • CRNX CRINETICS PHARMACEUTICALS IN · prev qtr: $45.73M
  • IWM ISHARES TR · prev qtr: $18.78M
  • XBI SPDR SERIES TRUST · prev qtr: $10.67M
  • FTH FAETH THERAPEUTICS INC · prev qtr: $9.03M
  • PCSC PERCEPTIVE CAP SOLUTIONS COR · prev qtr: $7.34M
  • BHF BRIGHTHOUSE FINL INC · prev qtr: $6.05M
  • DGACU Disciplined Growth Acquis Co Unit 99/99/9999 · prev qtr: $5.02M
  • ATAI ATAI LIFE SCIENCES NV · prev qtr: $4.81M

Insider Transactions (Form 4)

Latest ADAR1 Capital Management, LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

Transaction date Activity Security Shares Price Filing
2026-11-11 Buy NextCure, Inc. 12,333 $5.10 SEC filing
2026-11-06 Buy NextCure, Inc. 3,662 $5.10 SEC filing
2026-11-05 Buy InMed Pharmaceuticals Inc. 2,640 $13.10 SEC filing
2026-11-05 Buy NextCure, Inc. 1,024 $5.10 SEC filing
2026-10-27 Buy NextCure, Inc. 3,553 $5.10 SEC filing
2026-10-26 Buy NextCure, Inc. 1,672 $5.03 SEC filing
2026-10-23 Buy InMed Pharmaceuticals Inc. 4 $1.32 SEC filing
2026-10-23 Buy NextCure, Inc. 5,626 $4.83 SEC filing

All insider transactions →

Fund Profile

ADAR1 Capital Management, LLC is an SEC-registered 13F filer based in Austin, TX, United States. As of Q3 2026 it reported 259 US equity positions with a combined value of $1.98B. HoldingsHub carries 12 quarters of its filings (Q4 2023–Q3 2026).

Firm Snapshot

  • Headquarters: AUSTIN, TX, United States
  • SEC registration: 801-130082 (status: Approved), registered 2024-04-25
  • Regulatory AUM (Form ADV): $1.68B as of 2026-03-31
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 2 private funds, of which 2 hedge funds

Portfolio Structure

  • 259 positions · $1.98B reported value (Q3 2026)
  • Top 10 holdings = 37.7% of reported value
  • Largest position: SPY (STATE STR SPDR S&P 500 ETF T) at 6.9%
  • Average position size: $7.63M

Sector Tilt

  • Health Care 85.7%
  • Financials 3.1%
  • Industrials 0.3%
  • (classified holdings cover 89% of value)

Quarterly Activity

  • Q3 2026: 33 new, 78 added, 63 reduced, 42 exited
  • 85 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

AI Rebalance Analysis

1. Overall direction and market view: Aggressive growth tilt, with significant new positions (33) and a 7x increase in SPY exposure, suggesting bullish market sentiment and tactical diversification. 2. Key moves: - Added: SPY (7.44% wt, +610.5% shares), DNLI (2.35% wt, +101.3% shares), SEPN (2.09% wt, +3.6% shares), AURA (1.86% wt, +4038.1% shares). - Reduced: PTGX (7.36% wt, -1.0% shares), ROIV (6.18% wt, -2.5% shares), IMVT (3.92% wt, -9.2% shares), AGIO (2.08% wt, -11.5% shares). 3. Portfolio structure: Active, biotech/Health Care-heavy (80% of top 10), high-risk (small/mid-cap biotech names), with a modest passive overlay (SPY). 4. Per-holding one-liner: - SPY: S&P 500 ETF (benchmark). - PTGX: Biopharma (unverified). - ROIV: Biotech (unverified). - IMVT: Biotech (unverified). - DNLI: Neurology biotech (unverified). - BOXX: EA Trust (unverified). - SEPN: Gastroenterology biotech (unverified). - AGIO: Cancer metabolism biotech (unverified). - AURA: Oncology biotech (unverified). - INSM: Rare disease biotech (unverified). 5. Style summary: High-conviction biotech bets with opportunistic S&P 500 exposure.

Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice. · AI generated 2026-11-17 04:26

Sector Allocation

Health Care 85.7%
Financials 3.1%
Other 10.9%
Sort by: Value · CSV
# Shares Value Weight Allocation Change
1 177.62K $135.46M 6.86%
6.86%
Add
2 951.40K $134.04M 6.78%
6.78%
Reduce
3 3.08M $112.62M 5.70%
5.70%
Reduce
4 3.38M $89.07M 4.51%
4.51%
Hold
5 2.12M $71.46M 3.62%
3.62%
Reduce
6 1.16M $43.22M 2.19%
2.19%
Add
7 2.07M $42.83M 2.17%
2.17%
Add
8 337.12K $39.91M 2.02%
2.02%
Hold
9 974.40K $38.13M 1.93%
1.93%
Add
10 1.14M $37.89M 1.92%
1.92%
Reduce
11 5.39M $33.82M 1.71%
1.71%
Add
12 229.53K $26.20M 1.33%
1.33%
Hold
13 799.30K $25.91M 1.31%
1.31%
Add
14 3.24M $25.15M 1.27%
1.27%
Add
15 6.65M $24.60M 1.25%
1.25%
Add
16 2.16M $24.14M 1.22%
1.22%
Reduce
17 2.01M $23.65M 1.20%
1.20%
Add
18 1.73M $22.85M 1.16%
1.16%
Add
19 8.89M $22.84M 1.16%
1.16%
Hold
20 237.57K $21.15M 1.07%
1.07%
Reduce
21 442.68K $20.29M 1.03%
1.03%
Add
22 813.24K $19.28M 0.98%
0.98%
Add
23 464.60K $19.16M 0.97%
0.97%
Add
24 87.51K $17.96M 0.91%
0.91%
Hold
25 952.06K $17.35M 0.88%
0.88%
Add
26 637.35K $17.32M 0.88%
0.88%
Add
27 997.36K $15.96M 0.81%
0.81%
Reduce
28 926.35K $15.93M 0.81%
0.81%
Hold
29 258.18K $15.63M 0.79%
0.79%
Add
30 369.79K $15.02M 0.76%
0.76%
Add
31 3.06M $14.90M 0.75%
0.75%
Add
32 179.03K $14.26M 0.72%
0.72%
Reduce
33 823.88K $14.24M 0.72%
0.72%
Add
34 138.66K $13.20M 0.67%
0.67%
Add
35 1.52M $12.76M 0.65%
0.65%
Reduce
36 1.14M $12.60M 0.64%
0.64%
Add
37 392.42K $12.57M 0.64%
0.64%
Add
38 16.45K $12.47M 0.63%
0.63%
Reduce
39 135.59K $12.43M 0.63%
0.63%
Hold
40 6.52M $12.33M 0.62%
Form 4 · 3 →
0.62%
Add
41 1.01M $12.02M 0.61%
0.61%
Add
42 822.16K $12.00M 0.61%
0.61%
New
43 185.62K $11.91M 0.60%
0.60%
Hold
44 5.71M $11.73M 0.59%
0.59%
Reduce
45 4.56M $11.36M 0.57%
0.57%
Reduce
46 397.72K $11.33M 0.57%
0.57%
Add
47 276.35K $10.94M 0.55%
0.55%
Reduce
48 433.81K $10.82M 0.55%
0.55%
Add
49 366.97K $10.68M 0.54%
0.54%
Add
50 1.00M $10.52M 0.53%
0.53%
Hold

Holdings Prediction Model

Predicts next-quarter Top-10 holdings and weights from the fund's own historical trading轨迹 (add / reduce / hold) plus each stock's price momentum and relative volume. Strictly no look-ahead: a prediction for quarter T+1 uses only data through quarter T. Weights are shares of the modelled portfolio.

The next-quarter predicted Top 10 (2026-Q4) is shown in the «Latest Q · Forecast» tab above, in the same holdings format. That view is for logged-in accounts: 3 views per day on Free, unlimited on Gold/Diamond.

Latest-Quarter Accuracy (2026-Q3)

P 60% R 60% F1 60% (modelled on 2026-Q2; 6/10 hit)

Low-confidence forecast This fund replaces about 39% of its Top-10 each quarter and backtests at F1 62% (threshold 80%). Holdings in high-turnover portfolios cannot be forecast from their own history; the figures below are illustrative.

Historical Backtest (10 quarters)

Avg precision 62% · recall 62% · F1 62% · avg rank error 2.9 · Top-10 turnover 39%

Quarter Prec. Recall F1 Predicted Top 10 Actual Top 10
2024-Q2 60% 60% 60% BOXX · ROIV · SPY · PTGX · KROS · RPRX · MACK · ASND · ABUS · AVRO PTGX · ROIV · BOXX · RPRX · KROS · IMVT · ABUS · MRK · RZLT · SLDB
2024-Q3 40% 40% 40% PTGX · ROIV · BOXX · RPRX · KROS · IMVT · ABUS · MRK · SLDB · EWTX PTGX · BBIO · BOXX · ROIV · RPRX · ASND · ZURA · ZLAB · KNSA · AAM
2024-Q4 40% 40% 40% PTGX · BBIO · ROIV · BOXX · RPRX · ASND · ZURA · ZLAB · KNSA · AAM ROIV · BOXX · ZLAB · IMVT · IKT · BIL · ABVX · MLYS · ASND · PCSC
2025-Q1 70% 70% 70% ROIV · BOXX · ZLAB · IMVT · IKT · BIL · ABVX · MLYS · ASND · RVMD PTGX · BOXX · ROIV · ZLAB · IMVT · CYTK · KROS · ABVX · BIL · IKT
2025-Q2 70% 70% 70% PTGX · BOXX · ZLAB · ROIV · IMVT · CYTK · KROS · ABVX · BIL · IKT KROS · PTGX · BOXX · ZLAB · ABVX · ROIV · PRTA · CYTK · SPY · CGON
2025-Q3 80% 80% 80% KROS · PTGX · BOXX · ZLAB · ABVX · PRTA · CYTK · ROIV · SPY · CGON ABVX · KROS · PTGX · ROIV · BOXX · IMVT · ETNB · SPY · ZLAB · CYTK
2025-Q4 70% 70% 70% ABVX · KROS · PTGX · ROIV · IMVT · BOXX · ETNB · SPY · CYTK · ZLAB ABVX · PTGX · ROIV · IMVT · RNAM · BOXX · SPY · CYTK · SEPN · ABUS
2026-Q1 60% 60% 60% ABVX · PTGX · ROIV · IMVT · RNAM · SPY · BOXX · CYTK · SEPN · ABUS PTGX · ROIV · IMVT · SPY · CYTK · CRNX · BOXX · DNLI · BEAM · ZLAB
2026-Q2 70% 70% 70% PTGX · ROIV · IMVT · SPY · CRNX · CYTK · DNLI · BOXX · BEAM · ZLAB PTGX · ROIV · IMVT · ZLAB · AGIO · CRNX · BOXX · CYTK · SEPN · AVR
2026-Q3 ★ 60% 60% 60% PTGX · ROIV · IMVT · ZLAB · AGIO · CRNX · BOXX · CYTK · AVR · SEPN SPY · PTGX · ROIV · IMVT · DNLI · BOXX · SEPN · AGIO · AURA · INSM

★ = latest filed quarter (predicted vs actual). Recall = share of the real Top 10 caught by the model; precision = share of the predicted Top 10 that were real.

Barra Factor Attribution

The disclosed long US equity book from the 2026-Q3 13F is held at its report-date weights and decomposed over 2026-09-30 ~ 2026-11-16. The model uses 16 Barra style factors plus GICS sector dummies, WLS cross-sectional factor returns and an EWMA factor covariance for risk. The “portfolio” is the visible 13F book, not the fund's true NAV.

13F periodQ3 2026 Attribution quarterQ4 2026 (in progress) Window2026-09-30 → 2026-11-16 Trading days33 Holdings33 Model coverage100.0%

The quarter is not complete yet; the window ends at the latest available price date, 2026-11-16, and will update as prices arrive.

Portfolio return-1.64%Buy & hold
QQQ synthetic benchmark-17.01%Liquidity weighted
Excess return+15.38%vs benchmark
Barra annualised vol27.7%Model estimate
Realised vol29.1%Annualised in window
Weighted beta0.85Raw exposure
Factor / specific risk64% / 36%Share of variance
Top-10 concentration92.4%Of reported value
Portfolio value (start = 100)78.385.292.098.9105.710-0110-2311-16ADAR1 Capital Management, LLCQQQ syntheticLiquid universe EW
Start = 100. Red = portfolio, dark = QQQ synthetic benchmark, dashed grey = equal-weight model universe.

1. Performance

Metric Value Note
Portfolio return (buy & hold)-1.64%Disclosed long book
QQQ synthetic benchmark-17.01%Liquidity-weighted constituents
Model universe, equal weight-1.70%Opportunity-cost reference
Excess return+15.38%Portfolio − benchmark
Arithmetic return sum-1.11%Difference vs compounded is the cross term
Weighted raw beta0.85Weighted holding betas
Realised volatility (annualised)29.08%Daily returns in window
Barra model volatility (annualised)27.70%Factor + specific
Factor share of variance63.5%Barra factors
Specific share of variance36.5%Stock residuals
Reported value$567.1M13F long US equity

2. Return attribution

The -1.11% arithmetic return splits into style factors, sector factors and specific return; the table is sorted by contribution.

Factor group Factors Contribution Share of |return|
Size & Liquidity 6 +0.06% 5.6%
Momentum & Growth 3 -5.07% -458.7%
Volatility & Tail Risk 7 +2.05% 185.2%
Industry 12 +7.35% 664.1%
Specific 1 -5.49% -496.2%
Return attribution (style + industry, %)-5.7-2.8+0.0+2.8+5.7Leverage (Downside Vol)+0.54Growth-0.64Size+0.66Historical Volatility-0.92Amihud Illiquidity-0.99Max Drawdown-1.40Mid Cap-1.84Other+2.10Non-linear Size+2.32Residual Volatility+2.49Skewness-3.16Kurtosis+4.57Momentum-4.61Health Care+5.24
Factor Type Exposure Factor return Contribution Share of |return|
Health Care Industry +0.75 +6.98% +5.24% 473.3%
Kurtosis Style +0.61 +7.51% +4.57% 413.0%
Residual Volatility Style +0.76 +3.29% +2.49% 225.1%
Non-linear Size Style +2.30 +1.01% +2.32% 210.1%
Other Industry +0.24 +8.78% +2.10% 190.2%
Size Style -0.34 -1.95% +0.66% 59.8%
Leverage (Downside Vol) Style -0.32 -1.71% +0.54% 49.0%
Short-term Reversal Style +0.20 +0.87% +0.18% 16.1%
Liquidity Style +0.28 +0.36% +0.10% 9.2%
Beta Style -0.02 +4.44% -0.07% -6.7%
Turnover Style +0.04 -4.80% -0.19% -17.6%
Growth Style -0.37 +1.75% -0.64% -58.3%
Historical Volatility Style +0.07 -14.00% -0.92% -82.9%
Amihud Illiquidity Style +2.22 -0.45% -0.99% -89.5%
Max Drawdown Style +0.80 -1.76% -1.40% -126.8%
Mid Cap Style +0.95 -1.94% -1.84% -166.3%
Skewness Style +0.72 -4.39% -3.16% -285.4%
Momentum Style +1.15 -4.00% -4.61% -416.5%
Specific Specific — — -5.49% -496.2%

3. Risk attribution

Annualised volatility is 27.70%; factor risk explains 63.5% of variance and specific risk 36.5%. A negative variance contribution means the factor is negatively correlated with the rest of the book and acts as a partial hedge.

Risk attribution (share of variance, %)-39.4-19.7+0.0+19.7+39.4Growth-0.25Leverage (Downside Vol)+0.25Non-linear Size+0.48Liquidity+0.69Kurtosis+0.90Max Drawdown+1.82Size+1.84Residual Volatility+3.02Mid Cap+3.57Amihud Illiquidity+8.85Momentum+10.20Other+10.53Health Care+21.36Specific+36.47
Factor Type Exposure Share of variance Vol contribution Share of vol
Specific Specific — 36.5% +10.10% 10.1%
Health Care Industry +0.75 21.4% +5.92% 5.9%
Other Industry +0.24 10.5% +2.92% 2.9%
Momentum Style +1.15 10.2% +2.82% 2.8%
Amihud Illiquidity Style +2.22 8.8% +2.45% 2.5%
Mid Cap Style +0.95 3.6% +0.99% 1.0%
Residual Volatility Style +0.76 3.0% +0.84% 0.8%
Size Style -0.34 1.8% +0.51% 0.5%
Max Drawdown Style +0.80 1.8% +0.50% 0.5%
Kurtosis Style +0.61 0.9% +0.25% 0.2%
Liquidity Style +0.28 0.7% +0.19% 0.2%
Non-linear Size Style +2.30 0.5% +0.13% 0.1%
Leverage (Downside Vol) Style -0.32 0.2% +0.07% 0.1%
Beta Style -0.02 -0.2% -0.06% -0.1%
Growth Style -0.37 -0.2% -0.07% -0.1%

4. Style exposures

Standardised z-scores; positive means the book leans toward that style versus the model universe, negative means underweight.

Style exposures (z-score)-0.9-0.10.81.72.6Max DrawdownKurtosisSkewnessLeverage (Downside Vol)GrowthTurnoverAmihud IlliquidityLiquidityHistorical VolatilityResidual VolatilityShort-term ReversalMomentumBetaMid CapNon-linear SizeSizePortfolioQQQ benchmark
Style factor Portfolio QQQ benchmark Difference
Size -0.34 +2.10 -2.44
Non-linear Size +2.30 +1.68 +0.63
Mid Cap +0.95 +0.13 +0.82
Beta -0.02 +1.29 -1.31
Momentum +1.15 +0.72 +0.43
Short-term Reversal +0.20 -0.64 +0.85
Residual Volatility +0.76 -0.40 +1.16
Historical Volatility +0.07 +0.86 -0.79
Liquidity +0.28 +0.11 +0.17
Amihud Illiquidity +2.22 +1.16 +1.06
Turnover +0.04 +0.21 -0.17
Growth -0.37 +0.58 -0.95
Leverage (Downside Vol) -0.32 +0.14 -0.46
Skewness +0.72 +0.24 +0.48
Kurtosis +0.61 +0.21 +0.39
Max Drawdown +0.80 -0.08 +0.88

5. Industry allocation & Brinson

Industry allocation (weight, %)-7.515.037.560.082.5Information TechnologyCommunication ServicesUtilitiesConsumer StaplesConsumer DiscretionaryIndustrialsOtherHealth CarePortfolioQQQ benchmark
Sector Portfolio Benchmark Portfolio ret Benchmark ret Allocation Selection Interaction Total
Information Technology 0.0% 73.6% +0.00% -22.33% +3.83% +16.44% -16.44% +16.44%
Other 24.0% 0.0% +2.19% +0.00% +4.10% +0.00% +0.52% +0.52%
Communication Services 0.0% 2.6% +0.00% -17.64% +0.01% +0.46% -0.46% +0.46%
Utilities 0.0% 0.8% +0.00% +11.13% -0.22% -0.09% +0.09% -0.09%
Consumer Staples 0.0% 0.8% +0.00% +15.26% -0.27% -0.13% +0.13% -0.13%
Consumer Discretionary 0.1% 8.8% -7.86% +3.76% -1.82% -1.02% +1.01% -0.34%
Industrials 0.8% 11.1% +3.77% +4.36% -2.21% -0.07% +0.06% -0.45%
Health Care 75.0% 1.7% -3.20% +8.29% +18.61% -0.20% -8.41% -2.55%
Total +21.95% +15.37% -23.50% +13.82%

6. Holdings & contribution

Symbol Name Sector Weight Return Contribution QoQ
SPY STATE STR SPDR S&P 500 ETF T Other 23.89% +2.16% +0.52% Add
PTGX PROTAGONIST THERAPEUTICS INC Health Care 23.64% -11.40% -2.69% Reduce
ROIV ROIVANT SCIENCES LTD Health Care 19.86% +5.58% +1.11% Reduce
DNLI DENALI THERAPEUTICS INC Health Care 7.55% -12.53% -0.95% Add
INSM INSMED INC Health Care 4.62% +7.66% +0.35% Hold
RVMD REVOLUTION MEDICINES INC Health Care 3.17% -18.70% -0.59% Hold
MAZE MAZE THERAPEUTICS INC Health Care 3.06% +24.72% +0.76% Add
TSHA TAYSHA GENE THERAPIES INC Health Care 2.63% -16.63% -0.44% Add
REGN REGENERON PHARMACEUTICALS Health Care 2.20% +25.60% +0.56% Reduce
BEAM BEAM THERAPEUTICS INC Health Care 1.81% -14.36% -0.26% New
CTNM CONTINEUM THERAPEUTICS INC Health Care 0.91% -27.94% -0.26% Add
DHR DANAHER CORP DEL Industrials 0.83% +3.77% +0.03% Reduce
ONC BEONE MEDICINES LTD Health Care 0.76% +12.39% +0.09% Hold
RLAY RELAY THERAPEUTICS INC Health Care 0.68% -4.32% -0.03% Reduce
ISRG INTUITIVE SURGICAL INC Health Care 0.66% +7.65% +0.05% Add
BBIO BRIDGEBIO PHARMA INC Health Care 0.55% +17.57% +0.10% Hold
NAMS NEWAMSTERDAM PHARMA COMPANY Health Care 0.51% -19.98% -0.10% Hold
MDT MEDTRONIC PLC Health Care 0.38% +19.23% +0.07% New
TNGX TANGO THERAPEUTICS INC Health Care 0.34% -3.13% -0.01% Hold
BSX BOSTON SCIENTIFIC CORP Health Care 0.28% +0.09% +0.00% Add
Contribution rank Symbol Sector Weight Return Contribution
1 ROIV Health Care 19.86% +5.58% +1.11%
2 MAZE Health Care 3.06% +24.72% +0.76%
3 REGN Health Care 2.20% +25.60% +0.56%
4 SPY Other 23.89% +2.16% +0.52%
5 INSM Health Care 4.62% +7.66% +0.35%
6 BBIO Health Care 0.55% +17.57% +0.10%
7 ONC Health Care 0.76% +12.39% +0.09%
8 MDT Health Care 0.38% +19.23% +0.07%
9 BEAM Health Care 1.81% -14.36% -0.26%
10 TSHA Health Care 2.63% -16.63% -0.44%
11 RVMD Health Care 3.17% -18.70% -0.59%
12 DNLI Health Care 7.55% -12.53% -0.95%
13 PTGX Health Care 23.64% -11.40% -2.69%

7. Conclusions

  1. Over the attribution window 2026-09-30 → 2026-11-16 (33 trading days), the reported portfolio returned -1.64%, versus -17.01% for the QQQ synthetic benchmark — an excess of +15.38%.
  2. Return attribution: the largest positive style/industry contributions came from Health Care +5.24%, Kurtosis +4.57%, Residual Volatility +2.49%; the largest drags came from Momentum -4.61%, Skewness -3.16%, Mid Cap -1.84%. Specific (stock-level) return contributed -5.49%.
  3. Risk attribution: Barra model volatility is 27.70% annualised; factor risk explains 64% of variance and specific risk 36%. The largest factor risk sources are Health Care 21.4%, Other 10.5%, Momentum 10.2%.
  4. Style tilt: size -0.34, momentum +1.15, volatility +0.07, liquidity +0.28; the weighted raw beta is 0.85. Positive z-scores mean the portfolio leans toward that style versus the cross-section.
  5. Industry: the largest overweight versus the benchmark is Health Care (+73.2 pp), the largest underweight is Information Technology (-73.6 pp). Allocation contributed +21.95%, selection +15.37% and interaction -23.50%.
  6. Concentration: the top-10 positions are 92.4% of the attributed portfolio and the model covers 100.0% of its value with full style exposures. This is a high-conviction, long-only 13F book — not the fund's complete NAV.
Methodology & caveats
  • 13F discloses long US equity (including some options) only; cash, shorts and non-US positions are absent. This is not the fund's true NAV.
  • Weights are the report-date reported values and stay fixed over the window (buy & hold); intra-quarter trading and flows are not captured.
  • Factor exposures are measured at quarter end and held through the next quarter; style factors are cross-sectionally orthogonalised and read as incremental exposures.
  • The database has no share-count data, so size and liquidity use dollar volume (price × volume) as a proxy; Size is closer to “traded-value scale”.
  • Factor returns come from a WLS cross-sectional regression on the model universe; risk is annualised, and some factor variance contributions can be negative.
  • 13F filings lag by up to 45 days, so the stretch from the report date to the filing date was not actionable in real time.
  • Sector mapping uses one consistent GICS level-1 scheme for both the portfolio and the benchmark.

FAQ

What did ADAR1 Capital Management, LLC buy in 2026-Q3?

In its 2026-Q3 13F filing, ADAR1 Capital Management, LLC reported 259 equity positions worth $1.98B in aggregate; its largest disclosed positions were SPY ($135.46M), PTGX ($134.04M), ROIV ($112.62M).

How large is ADAR1 Capital Management, LLC's portfolio?

ADAR1 Capital Management, LLC reported $1.98B of long equity holdings across 259 positions as of 2026-Q3. Top-10 holdings account for 37.7% of reported value.

What is ADAR1 Capital Management, LLC's investment style?

HoldingsHub classifies the portfolio as Mid / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/adar1-capital-management/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →